Lycia Therapeutics Files for Nasdaq IPO, Offering 17.64 Million Shares
Lycia Therapeutics is offering 17,640,000 common shares at $18.00 each. The shares are expected to trade on the Nasdaq Global Select Market under ticker LYCA.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
Lycia Therapeutics files for IPO on Nasdaq under symbol LYCA
Lycia Therapeutics has filed for an initial public offering of its common stock on the Nasdaq, aiming to trade under the symbol 'LYCA'. Jefferies, TD Cowen, Evercore ISI, Guggenheim Securities, and Lifesci Capital are listed as underwriters.
Lycia Therapeutics Files for Nasdaq IPO
Lycia Therapeutics, a clinical-stage biotech developing drugs that degrade disease-causing extracellular proteins, has filed for an initial public offering to list on the Nasdaq Global Market under the ticker LYCA. Proceeds are intended to fund clinical programs in allergic diseases and Graves' disease.